Progression of systemic lupus erythematosus associated with propofol administration: a case report. Issue 4 (13th July 2017)

• Record Type: Journal Article
• Authors: Yu, Yang; Gui, Huan; Xiong, Kai; Fang, Xiangdong; He, Jiake
• Is Part Of: European journal of hospital pharmacy. Volume 25:Issue 4(2018)
• Page Start: 225
• Page End: 227
• Publication Date: 2017-07-13
• Subjects: Propofol -- systemic lupus erythematosus -- Adverse events -- immunosuppressive medications -- exacerbated symptoms; Pharmacy -- Periodicals; Hospital pharmacies -- Periodicals; 615.1
• DOI: 10.1136/ejhpharm-2017-001255
• Languages: English
• ISSNs: 2047-9956

Abstract

Abstract : Propofol is a sedative-hypnotic agent used as a general anaesthetic with a good safety profile. However, the potential risk for patients with systemic lupuserythematosus (SLE) receiving propofol remains unclear. We report the case of a patient who received an intravenous infusion of propofol for painless gastroscopy which exacerbated acute SLE despite no history of allergies. The adverse effect might be because propofol increased T helper cells and trigged the induction of B cell differentiation and plasmablast formation, which further promoted the secretion of auto-antibodies. This case shows that propofol can exacerbate SLE symptoms in some patients and highlights the importance of identifying potential immune-related factors before propofol administration, especially in patients with autoimmune diseases. It is important to be aware of and differentiate this uncommon and non-specific SLE manifestation from a myriad of disorders presenting with a primary digestive disorder in the outpatient clinic.